Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 5/20 | 0.32 |
| ▸ | CTSK | P43235 | 4/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23805208 | 1.00 | GRN (0.41) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL22651723 | 0.83 | GRN (0.37) | GRNSORT1MAPK1CA1CA2 | |
| SCHEMBL28257698 | 0.83 | CTSK (0.46) | CYP2C9CA1CA2CTSSCTSK | |
| SCHEMBL23822625 | 0.83 | CTSK (0.46) | CYP2C9CA1CA2CTSSCTSK | |
| SCHEMBL13955236 | 0.83 | CTSK (0.46) | CYP2C9CA1CA2CTSSCTSK | |
| SCHEMBL4682422 | 0.82 | GRN (0.43) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL18515857 | 0.82 | GRN (0.56) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL2568153 | 0.79 | GRN (0.43) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL20293785 | 0.78 | — | — | |
| SCHEMBL20293784 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4117647-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | Purdue Research Foundation (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021183370-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159475-A1 | COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF | CD47, CD74, ICOS | GRN 839/4885SORT1 1590/4885MAPK1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.